The invention provides a method for the treatment of Ph+ leukemia in a patient comprising administering to the patient (i) a BCR-ABL tyrosine kinase inhibitor, and (ii) an agent which selectively binds to a cell surface receptor expressed on Ph+ leukemic stem cells. The invention further provides for the use of (i) and (ii) in, or in the manufacture of a medicament for, the treatment of Ph+ leukemia in a patient and a composition for the treatment of Ph+ leukemia in a patient comprising (i) and (ii) and kits comprising (i) and (ii). In some embodiments, the tyrosine kinase inhibitor is or is not imatinib or is selected from the group consisting of dasatinib, nilotinib, bosutinib, axitinib, cediranib, crizotinib, damnacanthal, gefitinib, lapatinib, lestaurtinib, neratinib, semaxanib, sunitinib, toceranib, tyrphostins, vandetanib, vatalanib, INNO-406, AP24534, XL228, PHA-739358, MK-0457, SGX393 and DC2036 or is selected from the group consisting of dasatinib and nilotinib. In some embodiments, the agent binds to a receptor involved in signalling by at least one of IL-3, G-CSF and GM-CSF. In some embodiments, the agent is a mutein selected from the group consisting of IL-3 muteins, G-CSF muteins and GM-CSF muteins. In some embodiments, the mutein is an IL-3 mutein. In some embodiments, the agent is a soluble receptor which is capable of binding to IL-3.Linvention concerne un procédé pour traiter la leucémie Ph+ chez un patient consistant à : administrer à ce patient (i) un inhibiteur de la tyrosine kinase BCR-ABL, et (ii) un agent qui se lie sélectivement à un récepteur de surface cellulaire exprimé sur des cellules leucémiques Ph+ souches. Linvention concerne également lutilisation de (i) et de (ii) dans un médicament ou dans sa production, pour traiter la leucémie Ph+ chez un patient une composition pour traiter la leucémie Ph+ chez un patient comprenant (i) et (ii) et des kits comprenant (i) et (ii). Dans des modes de réalisation, linhibiteur de la tyrosine kinase
